The Chairman informed Board members that the NSP 2022 and associated Plans had been submitted to the Minister for approval on 23 November 2021, following adoption by the Board. A formal response was received from the Minister, advising that the Minister had approved the NSP 2022 subject to the amendments contained within the letter being made. A meeting of the Board will be arranged to consider and adopt the final version of NSP 2022 during the week beginning 7 February.
The Board discussed with the CEO and EMT the key aspects from the CEO Report which had been circulated prior to the meeting. The discussion focused on Our Lady’s Hospital Navan, South Kerry CAHMS Look Back Review, the Health and Safety Authority prosecution involving Our Lady’s Hospital Navan, the Board Strategic Scorecard, the Implementation and Reporting on Conti Review Report, an update on the transfer of policy and funding responsibility for the Specialist Community Based Disability Services from the DOH to DCEDIY, an Omicron Variant Update, a on the ‘Brandon’ Report, and Health Sector Resourcing.
The CEO informed the Board that the key test and trace indicators over the last week are showing a rapid downward trend in demand and positivity relative to the previous week and that community referrals have decreased by 55% compared to the previous week. The CEO noted that despite the rapid increase in positive cases in the country, the number of patients in hospital and in ICU has remained stable.
The Board were informed that in light of the current trends the Test and Trace Programme have commenced a review of the National Test and Trace strategy, previously developed by the HSE. The Board emphasised that given the scale of the programme with over 3,000 staff, multiple partners and a nationwide infrastructure that is in place until June 2022 at a minimum, it is important that any major changes in testing strategy are fully cognisant of any possible future requirement to flex upward.
The Board discussed with the CCO the paper on COVID-19 Omicron variant which assessed the current understanding of the variant and the impact of Omicron on the pandemic. The Board considered the potential and challenges for a reduction in testing to lead to a possible increased spread of infection, resulting in increased illness and death despite a variant with lower death rates, as well as the potential impact as a result of waning immunity and immune evasion. It was requested that that future updates on the impact of Covid might consider the issue of Long Covid and the impact on the health of HSE staff and the limitations of antiviral therapeutics for certain populations who are at risk such as pregnant people. In response to questions from Board members on the overall level of risk to public health associated with the continuing spread of the Omicron and the available evidence from the current situation, the CCO informed the Board that the current risk profile for Ireland, based on this variant’s epidemiological course, is lower compared to previous waves but there is little reason to expect that the virus can be eradicated in the medium term.
The CEO informed the Board that cyber security resilience, multi annual funding for waiting lists, enhancement in primary care services through the Enhanced Community Care (ECC) programme and development of community health networks, improvements in mental health services, and the further building of trust and confidence in the health service are key areas of focus for the Executive.
The CEO reported on the engagement with St Vincent’s University Hospital (SVUH) and the National Maternity Hospital (NMH) on the concerns raised previously by the Board in regard to the legal and governance framework for the new hospital to be located at SUVH. He confirmed that the Board’s concerns regarding the current legal and governance framework had been outlined at a meeting on 21 January, which he had attended with the Secretary General, the Chair and CEO of both hospitals, and the Chief Strategy Officer. He reported that all parties expressed a desire to work cooperatively with a view to getting to a stage where any impediments to progressing with this crucial infrastructure are resolved.
The Board discussed with the CEO the extent of the patient safety and clinical governance concerns that continue for as long as OLHN continues to operate as a Model 3 Hospital, in circumstances where its staffing and its infrastructure and its resourcing generally is more consistent with that of a Model 2 Hospital. The HSE’s plans to move OLHN to a model 2 level hospital are clinically led and are fully aligned to Government policy as outlined in the Framework 2013 Government policy document of 2013 Securing the Future of Smaller Hospitals – A Framework for Change. The Board was informed that engagement with Oireachtas members needs to be scheduled as a matter of priority and the Chair will confirm this with the Minister. The Board requested a full briefing paper on the matter.
The Board discussed with the CEO the ongoing work around the recommendation within the Brandon Report. The CEO informed the Board of the Attorney General’s advice in relation to not publishing the full report and thanked the Safety and Quality Committee for their work on the matter. The Board discussed the progress of a confidential informal scoping exercise which aims to determine key learnings to improve service and patient safety. The ND HR informed the Board that the process remains ongoing and noting the importance of ensuring proper and fair due process and fair procedures are adhered to at all stages. The Board agreed that discussion on this matter highlights the need to review the Serious Incident Management Team process and the importance of communication of regulatory issues with the relevant professional bodies. The Board noted that the CCO is working on a revised process for informing regulatory bodies at an earlier stage.
The CEO informed the Board that following concerns raised about the clinical practice of a Non-Consultant Hospital Doctor in prescribing, care planning and diagnostics in CAMHS Area A by a Non-Consultant Hospital Doctor (NCHD2) and again by a Locum Consultant, Child and Adolescent Psychiatrist (CP1) in September 2020.
The Chief Officer of Cork Kerry CHO formally commissioned the Look-Back Review (LBR) in April 2021 and received in January 2022. The report was reviewed nationally by the National Director Community Operations, Chief Operations Officer, National Clinical Director Quality & Patient Safety, Head of Quality & Patient Safety and the National Clinical Advisor and Group Lead Mental Health, with any issues clarified. The Board discussed the concerns surrounding the environment which exists to allow such events to happen.
The CEO informed the Board on the ongoing legal matters arising out of an incident which took place in the former Department of Psychiatry, Navan prior to its closure. He noted that having considered the issues arising a decision has been taken to concentrate our efforts on improving the situation rather than seeking to enter a defence.
The Board discussed the role and objectives of the new Sláintecare Programme Board, noting that the Programme Board is to ensure clear oversight and alignment between the DoH and the HSE and that all programme matters are dealt with in a coordinated and timely manner between all relevant stakeholders.
The Board requested that a paper on the overall Sláintecare governance and reporting arrangements and the HSE Board’s role in same be provided for the next Board meeting.
The issue of the need to strengthening the HSE accountability process was discussed by the Board. The CEO referred to the work on the paper Strengthening Accountability in the HSE which was presented to the Board in November 2019 and update on in December 2020. It was agreed that a further update would be brought to the Boards February meeting.
The CEO informed the Board that Anne Marie Hoey has been officially appointed to the position of ND HR on a permanent basis following the PAS recruitment campaign. The Board welcomed this appointment.
The Board discussed with the CEO and ND HR the paper on the HSE’s Workforce resourcing which had been circulated in advance of the meeting. The ND HR informed the Board of the key actions underpinning the resourcing strategy for 2022 and outlined the key learning from 2020/2021 that have influenced the approach to these actions in 2022. The Board noted that health service employment levels, show an increase of +12,506 WTE up to and including December 2021 and welcomed this level of unprecedent recruitment, particularly in the context of the HSE’s average turnover levels during this period that requires in the order of 9,500 staff to be recruited each year in order to stand still, before any net growth is realised. The ND HR updated the Board on current recruitment initiatives being progressed in 2022 as part of the overall Resourcing strategy and the challenges in the context of the global shortage of the health care professionals.
The Board reviewed the scorecard which reports on the full year 2021 performance including November and December 2021, which was circulated in advance of the Board meeting and agreed its submission to the Minister in accordance with the reporting requirements set out in the Letter of Determination of 3 November 2020. The Board noted that the summary of the ratings across the December Board Strategic Scorecard reflected an increased rating to 3.05 from 2.95.